ExploreWatchlistsPricing
  1. US-listed companies
  2. Theravance Biopharma, Inc.
  3. Financials
  4. Capital expenditures

Theravance Biopharma, Inc. (TBPH)

Market cap
$849.63M
P/E ratio
8x
SummaryFinancials
Period EndCapital expenditures (Million USD)YoY (%)
Dec 31, 2025-0-87.35%
Dec 31, 2024-0-86.66%
Dec 31, 2023-2+334.97%
Dec 31, 2022-1-83.21%
Dec 31, 2021-3-48.52%
Dec 31, 2020-7+108.31%
Dec 31, 2019-3-56.13%
Dec 31, 2018-7+200.91%
Dec 31, 2017-2+12.69%
Dec 31, 2016-2-19.34%
Dec 31, 2015-3-14.81%
Dec 31, 2014-3

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat